Abstract
Methods Changes from baseline to endpoint (last evaluable visit) in Asthma Control Questionnaire (ACQ) scores were assessed in subjects from 3 Phase III trials (low[n=746], medium[n=781], and high-dose [n=728] previous ICS use). The ACQ categorizes asthma symptoms and use of rescue-medication using a 7-point scale (0=totally controlled, 6=severely uncontrolled). In two placebo controlled trials, subjects were randomized to receive MF/F (100/10μg or 200/10μg), MF (100μg or 200μg), F (10μg), or placebo (26 weeks; all twice-daily [BID] via metereddose inhaler [MDI]); In a non-placebo controlled trial, subjects were randomized to receive MF/F 200/10μg, MF/F 400/10μg, or MF 400μg (12 weeks; all BID via MDI).
Highlights
Convenient online submission Thorough peer review No space constraints or color figure charges Immediate publication on acceptance Inclusion in PubMed, CAS, Scopus and Google Scholar Research which is freely available for redistribution
Full list of author information is available at the end of the article
Research which is freely available for redistribution
Summary
From Canadian Society of Allergy and Clinical Immunology Annual Scientific Meeting 2011 Quebec, Canada.
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
